Education
About Us
Working with TipRanks
Follow Us
Orchestra BioMed Holdings (OBIO)
NASDAQ:OBIO
OBIO Stock Chart & Stats
$3.32
-$0.06(-1.07%)
At close: 4:00 PM EST
$3.32
-$0.06(-1.07%)
Day’s Range― - ―
52-Week Range$2.20 - $6.30
Previous CloseN/A
Volume15.92K
Average Volume (3M)323.04K
Market Cap
$244.49M
Enterprise Value$85.32M
Total Cash (Recent Filing)$95.82M
Total Debt (Recent Filing)$1.83M
Price to Earnings (P/E)―
Beta2.07
Next Earnings
Apr 01, 2026EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.40
Shares Outstanding56,464,730
10 Day Avg. Volume266,849
30 Day Avg. Volume323,035
Financial Highlights & Ratios
PEG Ratio-0.20
Price to Book (P/B)4.47
Price to Sales (P/S)55.83
P/FCF Ratio-2.90
Enterprise Value/Market Cap0.35
Enterprise Value/Revenue30.28
Enterprise Value/Gross Profit32.55
Enterprise Value/Ebitda-1.14
Forecast
1Y Price Target
$12.50Price Target Upside276.51% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Study ProgressManagement expects the BACKBEAT study of the atrioventricular interval modulation (AVIM) therapy to complete enrollment in mid-2026.
Partnership And InvestmentTerumo has agreed to invest an additional $20M in Orchestra through a new series of non-voting preferred stock.
Regulatory DesignationAVIM therapy has been granted Breakthrough Device designation by the FDA.
Bears Say
Orchestra BioMed Holdings News
OBIO FAQ
What was Orchestra BioMed Holdings’s price range in the past 12 months?
Orchestra BioMed Holdings lowest stock price was $2.20 and its highest was $6.30 in the past 12 months.
What is Orchestra BioMed Holdings’s market cap?
Orchestra BioMed Holdings’s market cap is $244.49M.
When is Orchestra BioMed Holdings’s upcoming earnings report date?
Orchestra BioMed Holdings’s upcoming earnings report date is Apr 01, 2026 which is in 95 days.
How were Orchestra BioMed Holdings’s earnings last quarter?
Orchestra BioMed Holdings released its earnings results on Nov 18, 2025. The company reported -$0.4 earnings per share for the quarter, missing the consensus estimate of -$0.397 by -$0.003.
Is Orchestra BioMed Holdings overvalued?
According to Wall Street analysts Orchestra BioMed Holdings’s price is currently Undervalued.
Does Orchestra BioMed Holdings pay dividends?
Orchestra BioMed Holdings does not currently pay dividends.
What is Orchestra BioMed Holdings’s EPS estimate?
Orchestra BioMed Holdings’s EPS estimate is -0.38.
How many shares outstanding does Orchestra BioMed Holdings have?
Orchestra BioMed Holdings has 56,464,730 shares outstanding.
What happened to Orchestra BioMed Holdings’s price movement after its last earnings report?
Orchestra BioMed Holdings reported an EPS of -$0.4 in its last earnings report, missing expectations of -$0.397. Following the earnings report the stock price went up 10.165%.
Which hedge fund is a major shareholder of Orchestra BioMed Holdings?
Currently, no hedge funds are holding shares in OBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Orchestra BioMed Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.50 (276.51% Upside)
$12.50 (276.51% Upside)
Blogger Sentiment
Neutral
OBIO Sentiment 50%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $2.0M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
-38.83%
12-Months-Change
Fundamentals
Return on Equity
-166.97%
Trailing 12-Months
Asset Growth
-40.84%
Trailing 12-Months
Company Description
Orchestra BioMed Holdings
Orchestra BioMed Holdings (OBIO) is a biomedical company focused on developing and commercializing innovative solutions to address significant unmet medical needs in the fields of cardiovascular disease and other chronic conditions. The company leverages its proprietary technology platforms to create advanced therapeutic devices, with a core emphasis on enhancing the efficacy and safety of existing treatments. OBIO's flagship products include the Virtue® Sirolimus-Eluting Balloon, aimed at treating peripheral artery disease, and various other devices designed to improve patient outcomes through minimally invasive procedures.
OBIO Stock 12 Month Forecast
Average Price Target
$12.50
▲(276.51% Upside)
Technical Analysis
Cardiff Oncology
―
Greenwich LifeSciences
―
Climb Bio
―
Cognition Therapeutics
―
Pyxis Oncology
―
Ownership Overview
28.85% Insiders
3.75% Mutual Funds
30.10% Other Institutional Investors
34.57% Public Companies and
Individual Investors